12:00 AM
 | 
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Omacetaxine mepesuccinate regulatory update

Teva said FDA accepted for review an NDA for omacetaxine to treat chronic myelogenous leukemia (CML) in patients who have resistance and/or intolerance to two or more tyrosine kinase inhibitors, including ...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >